IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks. Cambrex specializes in seamless technology transfers and quick onboarding to keep your program on track.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Cambrex offers cutting-edge capabilities in peptide development and manufacturing, combining innovative technologies, diverse applications and specialized expertise to meet the growing demand for peptide-based therapeutics.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
09.02.2026
East Rutherford, NJ – September 2, 2026 – Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Robert Green, Executive Vice President and Chief Financial Officer, has informed the company of his plans to pursue new professional opportunities. The company has appointed Alan Majewski as Executive Vice President and Chief Financial Officer, effective September 14th, 2026.
“On behalf of the Board and the entire Cambrex team, I want to thank Robert for his leadership and many contributions to Cambrex,” said Tom Loewald, President and Chief Executive Officer. “Robert has been an important member of our leadership team during a period of significant growth and transformation, helping strengthen the company’s financial position and supporting our strategic investments. We wish him continued success in his next chapter.”
Robert Green said, “It has been a privilege to serve as CFO of Cambrex and work alongside such a talented team. I am proud of what we have accomplished together and confident the company is well positioned for continued success.”
Alan Majewski joins Cambrex with extensive financial leadership experience, and a deep background in pharmaceutical services. In his new role, he will be responsible for the company’s global finance organization and will support Cambrex’s continued execution of its growth strategy.
“We are pleased to welcome Alan to Cambrex,” said Loewald. “His financial expertise, operational perspective, and leadership experience make him an excellent addition to our executive team as we continue to expand our capabilities and deliver value to our customers.”
Alan Majewski added, “Cambrex has built a strong reputation as a trusted partner to the pharmaceutical industry. I am excited to join the organization and look forward to working with the talented Cambrex team to support the company’s next phase of growth.”
About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.
With over 45 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs.